Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

From Apple Earnings Conference Call: Sees ‘Very Solid’ Sales Growth In Q1

-Reuters

byBenzinga Newsdesk

October 28, 2021

1 minute read

-Reuters

News

Vinco Ventures/ZASH Global’s Lomotif Unit Early Sunday Highlighted Special Guests Lil Nas X, The Kid Laroi Made Special Appearance At Electronic Daisy Carnival

By Benzinga Newsdesk

Today, 11:52 PM

Lomotif Launches Lomo TV At EDC, Streaming all kineticFIELD Performances and Exclusive Live Backstage Interviews with Lil Nas X and The Kid Laroi LAS VEGAS, Oct. 24, 2021 /PRNewswire/ -- Lomotif, the popular

BBIG

JAK Inhibitors Come Under EMA Scrutiny On Safety Concerns: All You Need To Know

By Vandana Singh

Today, 11:52 PM

Following the FDA's issuance of a safety warning regarding JAK inhibitors, the safety committee of the European Medicines Agency initiated a review of t

ABBV

Northland Capital Markets Maintains Outperform on Lumentum Holdings, Raises Price Target to $120

By Benzinga Newsdesk

Today, 11:52 PM

Northland Capital Markets analyst Tim Savageaux maintains Lumentum Holdings (NASDAQ:LITE) with a Outperform and raises the price target from $110 to $120.

LITE

Concert Pharmaceuticals Q4 EPS $(1.01) Misses $(0.73) Estimate, Sales $13.00K Up From $7.00K YoY

By Benzinga Newsdesk

Today, 11:52 PM

Concert Pharmaceuticals (NASDAQ:CNCE) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.73) by 38.36 percent. This is a 46.38 percent decrease over losses of $(0.69) per

CNCE

From Apple Earnings Conference Call: Sees ‘Very Solid’ Sales Growth In Q1

Related Posts

Vinco Ventures/ZASH Global’s Lomotif Unit Early Sunday Highlighted Special Guests Lil Nas X, The Kid Laroi Made Special Appearance At Electronic Daisy Carnival

JAK Inhibitors Come Under EMA Scrutiny On Safety Concerns: All You Need To Know

Northland Capital Markets Maintains Outperform on Lumentum Holdings, Raises Price Target to $120

Concert Pharmaceuticals Q4 EPS $(1.01) Misses $(0.73) Estimate, Sales $13.00K Up From $7.00K YoY